Medication for drug-resistant epilepsy: choosing a regimen, checking newer drugs and planning monitoring

After several medications have failed to control seizures, it is understandable to ask whether a stronger or newer medicine is available. The more useful clinical question is what the previous treatment experience shows and how the next choice addresses it. A medication plan should specify the seizure types being targeted, the expected effect on the existing regimen and the point at which benefit and tolerability will be reviewed. Drug optimization remains important, while comprehensive epilepsy assessment proceeds when drug resistance is established. ILAE: Drug-Resistant Epilepsy, definition and clinical resourcesJehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

A list of medicines tried does not show whether each was appropriate, tolerated or used adequately. Record generic names, formulations, actual dosing history, duration at the intended regimen, seizure changes and reasons for stopping. Ineffectiveness, rash, excessive sedation, interrupted supply and difficulty taking doses have different implications. The next clinician needs those distinctions to avoid repeating an unsuccessful or unsafe approach. NICE NG217: Principles of treatment, safety, monitoring and withdrawal
Chinese public manufacturer submission material identifies clobazam tablets for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome from age two. That document is useful for the stated product information, but it is not independent proof of superiority or a payment decision. A specialist should explain the rationale and local prescribing basis if considering a different clinical use. 宜昌人福：氯巴占片2024申报资料，国家医保局公示附件；用于产品信息非支付依据
Before the visit, send a current medication history and a recent seizure diary. Match Chinese and English generic names, formulations and strengths carefully. With liquids, distinguish milligrams from milliliters and confirm the measuring device. A hospital agreeing to assess the patient does not mean its pharmacy can dispense every overseas product already being used. 中国抗癫痫协会官方网站及CAAE癫痫地图入口

Quick answer

After several medications have failed to control seizures, it is understandable to ask whether a stronger or newer medicine is available. The more useful clinical question is what the previous treatment experience shows and how the next choice addresses it. A medication plan should specify the seizure types being targeted, the expected effect on the existing regimen and the point at which benefit and tolerability will be reviewed. Drug optimization remains important, while comprehensive epilepsy assessment proceeds when drug resistance is established. ILAE: Drug-Resistant Epilepsy, definition and clinical resources Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022

Full guide

After several medications have failed to control seizures, it is understandable to ask whether a stronger or newer medicine is available. The more useful clinical question is what the previous treatment experience shows and how the next choice addresses it. A medication plan should specify the seizure types being targeted, the expected effect on the existing regimen and the point at which benefit and tolerability will be reviewed. Drug optimization remains important, while comprehensive epilepsy assessment proceeds when drug resistance is established. ILAE: Drug-Resistant Epilepsy, definition and clinical resources Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022

Reconstruct previous treatment rather than counting drug names

A list of medicines tried does not show whether each was appropriate, tolerated or used adequately. Record generic names, formulations, actual dosing history, duration at the intended regimen, seizure changes and reasons for stopping. Ineffectiveness, rash, excessive sedation, interrupted supply and difficulty taking doses have different implications. The next clinician needs those distinctions to avoid repeating an unsuccessful or unsafe approach. NICE NG217: Principles of treatment, safety, monitoring and withdrawal

Old prescriptions, pharmacy records and photographs of packaging can help when details are uncertain. Mark uncertainty honestly rather than inventing a precise dose. Two appropriate and adequately used, tolerated schedules without sustained seizure freedom support the drug-resistance definition; merely trying two boxes does not. Equally, someone who does meet the definition does not have to exhaust every available medicine before discussing other treatments.

Match treatment to all relevant seizure types

The choice depends on whether seizures are focal, generalized or part of a particular epilepsy syndrome. Evidence in adults with focal seizures cannot simply be transferred to a young child with Dravet syndrome. Some medicines can worsen particular seizure types, making diagnostic review essential before increasing treatment. If the patient has brief lapses, jerks and convulsions, describe each rather than concentrating only on the most dramatic episode. ILAE: Updated classification of epileptic seizures, 2025 NINDS: Dravet Syndrome

Genetic findings sometimes inform medication selection, but the meaning depends on the disease and the mechanism of the specific variant. A gene name shared with another patient does not establish that the same prescription will help. Genetic counseling and specialist interpretation are particularly useful when a proposed treatment is justified by a laboratory result that the family has not yet discussed in detail. Krey et al.: Current practice in diagnostic genetic testing of the epilepsies, ILAE Genetics Commission, 2022

Use the 2026 guidance as a clinical resource, not a ranking

The third-generation antiseizure medication guideline published in 2026 considers newer agents across multiple practical questions. A Chinese translation appeared in the associated Chinese epilepsy journal. Its purpose is to support choices about use, interactions and particular patient groups; publication does not make older medicines obsolete or establish identical Chinese approval for every drug it discusses. Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26 第三代抗癫痫发作药物治疗癫痫的应用指南，中译，癫痫杂志2026;12(3):222–238

Ask what the proposed medicine adds for your particular seizures. Clarify whether the intention is substitution, temporary overlap during a switch or continuing combination treatment. The plan should also say what will happen if seizures improve but adverse effects become burdensome. Keeping an old medicine because it has a useful effect and removing one that mainly adds toxicity are both decisions requiring an individualized review.

Cenobamate now has a Chinese approval history to consider

As checked in September 2026, the Chinese developer's official product information states that cenobamate tablets received NMPA approval in 2025 for partial-onset seizures in adults with epilepsy. Describing the product simply as unapproved in China would therefore be out of date. That approval statement does not establish stock at a particular hospital, personal eligibility or a reimbursement entitlement; the receiving prescriber and pharmacy must confirm those details. 翼思生物官方产品资料：西诺氨酯2025年在中国获批成人部分性发作适应证

Cenobamate requires a planned gradual titration and review of interacting medicines. Current U.S. prescribing information addresses DRESS, QT shortening and clinically significant liver injury; familial short QT syndrome is a contraindication. The August 2025 label revision includes baseline liver assessment and evaluation during treatment when clinically indicated. Chinese pharmacovigilance information in April 2026 also reported the European liver-injury safety update. These issues belong in counseling before treatment begins. DailyMed: XCOPRI U.S. prescribing information, revised August 2025, current retrieval September 2026 福建省药监局药物警戒快讯2026年第4期：欧盟西诺氨酯肝损伤警示

Overseas labeling is evidence of identified safety concerns, not a substitute for the Chinese product's current authorized instructions. Slower titration does not mean severe hypersensitivity is impossible. Do not accelerate an escalation schedule to reach a desired effect before a journey or appointment. New fever, rash, facial swelling, jaundice or otherwise concerning systemic symptoms warrant prompt medical assessment.

Lacosamide brings cardiac conduction into the review

Lacosamide can be useful in selected regimens, but cardiac history and other medicines matter. The current U.S. label describes PR prolongation and related conduction or rhythm concerns, with ECG assessment recommended around initiation and stabilization for relevant higher-risk patients. A Chinese expert consensus published in 2026 provides additional local clinical context for appropriate use. DailyMed: Lacosamide prescribing information, February 2026 中国抗癫痫协会：拉考沙胺治疗癫痫中国专家共识，2026

Tell the clinician about fainting, palpitations, known conduction abnormalities and cardiac or blood-pressure medication. A new transient loss of consciousness should not automatically be counted as worsening epilepsy and treated with another dose increase. Whether cardiology assessment is needed depends on the individual findings. The aim is a risk-based plan, rather than assuming that everyone needs identical testing or that no one needs it.

Lamotrigine initiation and restarting need particular care

Lamotrigine can cause serious skin reactions, and patients cannot reliably identify which new rash will remain mild. Valproate coadministration and exceeding recommended starting or escalation regimens are among the factors relevant to risk. A new rash, especially with fever, mucosal involvement or systemic symptoms, requires immediate clinical advice rather than waiting until a routine review. DailyMed: Lamotrigine prescribing information, May 2026

After an interruption, do not simply return to a previously tolerated high dose. The prescriber must consider the length of the gap and other medicines when deciding whether initial titration needs to be repeated. Starting or stopping hormonal contraception can also affect management. Bring both prescriptions to the review so that changes made by different services do not become invisible to one another.

Count alertness and behavior alongside seizure improvement

Levetiracetam and other antiseizure medicines can be associated with changes in mood or behavior. Irritability, marked aggression, depression or a substantial loss of daily function should be discussed even when seizure frequency has fallen. Note the timing of symptoms in relation to starting treatment or changing the regimen, while allowing the clinician to assess other possible causes. DailyMed: Levetiracetam prescribing information, February 2026

These risks do not mean that everyone taking the drug will develop psychiatric symptoms. They mean that the follow-up conversation should include the patient's experience and, with permission, relevant observations from people close to them. Thoughts of self-harm, severe behavioral disturbance or rapid changes in mental state need timely help. Persistent ordinary sleepiness also deserves attention when it interferes with walking, eating, study or safe caregiving.

Clobazam and prescription cannabidiol require proper indications and monitoring

Chinese public manufacturer submission material identifies clobazam tablets for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome from age two. That document is useful for the stated product information, but it is not independent proof of superiority or a payment decision. A specialist should explain the rationale and local prescribing basis if considering a different clinical use. 宜昌人福：氯巴占片2024申报资料，国家医保局公示附件；用于产品信息非支付依据

The U.S. cannabidiol product EPIDIOLEX has a May 2026 label covering seizures associated with LGS, Dravet syndrome or tuberous sclerosis complex from age one. Liver injury and sedation are relevant safety issues, and combining it with clobazam increases exposure to clobazam's active metabolite. A regulated prescription formulation cannot be assumed equivalent to an uncharacterized cannabis oil. Its U.S. authorization does not establish routine Chinese access or permission for personal cross-border carriage. DailyMed: EPIDIOLEX cannabidiol U.S. prescribing information, May 2026

Some syndrome medicines require an ongoing specialist service

The current U.S. fenfluramine label covers seizures associated with Dravet syndrome and LGS from age two. It carries warnings about valvular heart disease and pulmonary arterial hypertension and requires echocardiographic monitoring. Obtaining the bottle is therefore only part of arranging treatment: the clinical assessment and follow-up must also be feasible. Chinese eligibility and access require separate verification. DailyMed: FINTEPLA fenfluramine U.S. prescribing information, October 2025

When another family mentions a drug online, bring the original information to the consultation and ask whether the syndrome, age group and treatment goal match. A childhood-onset syndrome may continue into adulthood, but formulation needs, body size and the responsible clinical service can change. A planned transition is more useful than assuming the original pediatric prescription can continue indefinitely without review.

Review the whole combination whenever one component changes

Adding a medication can alter exposure to another or compound dizziness, sleepiness and impaired coordination. A combination may be poorly tolerated even when each individual dose falls within its usual range. The prescriber or pharmacist should see all regular prescriptions, temporary medicines, contraception and supplements. The information should include recent discontinuations as well as additions, because removing an interacting drug can also change the balance. Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26 NICE NG217: Principles of treatment, safety, monitoring and withdrawal

If the change involves several steps, request a dated chart that clearly separates morning and evening administration and identifies which formulation is intended. Agree who updates that chart after a telephone consultation. When multiple caregivers prepare medicines from memory, an apparently reasonable regimen can turn into an accidental duplicate dose or omission. A single current written version is easier to follow.

Alcohol and extra sedatives are not harmless ways to manage poor sleep or distress during adjustment. Tell the treating team if either is being used. If a treatment becomes intolerable, make contact rather than silently abandoning one component and continuing the rest of a combination whose interactions may now be different.

Blood levels answer a question; they do not replace clinical assessment

Drug-level measurement can be useful for selected questions about adherence, toxicity, pregnancy or altered clearance. Interpretation depends on the drug, the time since the last dose and whether the regimen has recently changed. A value inside a laboratory reference range does not guarantee seizure control or freedom from adverse effects. A value outside it should not prompt an unsupervised correction. NICE NG217: Principles of treatment, safety, monitoring and withdrawal

Write the sampling time and last dose time beside the result when possible. Other monitoring is also medicine-specific: renal function, liver tests, blood counts or additional assessments are ordered according to the regimen and personal risks. Paying for the same broad panel every month is not a substitute for deciding which safety question needs to be answered.

Raise reproductive plans before changing the regimen

The AAN, AES and SMFM guidance emphasizes balancing seizure control with fetal risks and optimizing treatment before conception when possible. Medication selection still has to fit the epilepsy. Discovering a pregnancy is a reason for prompt specialist contact, not abrupt self-discontinuation. Folic acid planning and any additional monitoring should be incorporated into coordinated neurological and maternity care. AAN/AES/SMFM: Epilepsy and pregnancy guideline, official announcement, May 2024

Foreign age restrictions or pregnancy-prevention programs should not be quoted as Chinese rules. Ask for the plan that applies where treatment is being provided, including who will review changing needs during pregnancy and after delivery. Advice about vomiting, missed doses and access to urgent care should be available before those situations arise.

Separate maintenance medication from emergency medication

A long-term regimen aims to reduce future seizures. A prescribed rescue medicine has a different role in selected prolonged or clustered events and must come with clear caregiver instructions. Do not assume an extra tablet of a regular medicine is an equivalent emergency treatment. During a seizure, protect the person and follow the action plan; do not force pills or liquid into the mouth of someone who cannot swallow safely. CDC: First Aid for Seizures

The plan should specify when to call emergency services, what the trained caregiver is authorized to administer and what observation is required afterwards. Ask whether the rescue product and formulation used at home will be available during a visit to China, and arrange a clinician-approved alternative in advance if necessary. Product names alone may conceal different concentrations or routes.

Make a Chinese medication consultation workable after you leave

Before the visit, send a current medication history and a recent seizure diary. Match Chinese and English generic names, formulations and strengths carefully. With liquids, distinguish milligrams from milliliters and confirm the measuring device. A hospital agreeing to assess the patient does not mean its pharmacy can dispense every overseas product already being used. 中国抗癫痫协会官方网站及CAAE癫痫地图入口

If a new regimen requires gradual adjustment, establish how prescriptions, monitoring and adverse-effect review will continue after the return journey. Agree the next evaluation date and the findings that would justify earlier contact. For suspected serious hypersensitivity, timely medical assessment takes priority; FDA safety communication on levetiracetam and clobazam emphasizes that systemic warning symptoms can occur even before a visible rash. FDA safety communication: DRESS with levetiracetam and clobazam, November 2023

Sustainable improvement requires more than reaching a target on the prescription chart. The follow-up should assess seizures, tolerability and practical reliability, then decide whether the current balance remains worthwhile. When appropriately chosen medication still cannot achieve the agreed goals, proceed with the comprehensive assessment already discussed rather than allowing each new prescription to postpone it indefinitely. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022